LGND
New deal, same old royalty magic
Ligand Pharmaceuticals is back in its favorite lane: buying pieces of other companies’ future cash flows. This time, it’s acquired royalty and milestone payment rights tied to Santen Pharmaceutical’s Ryjunea, the first approved pharmacologic treatment in Europe and the UK to slow myopia progression in children.
Why this matters
On paper, this isn’t as flashy as a drug approval or a giant acquisition. But royalty deals are Ligand’s whole thing. It’s basically the corporate version of owning the parking meter instead of the car: you don’t build the product, but you still collect when it works.
For investors, the big question is whether Ryjunea becomes a meaningful long-tail revenue stream. If the drug catches on, Ligand gets to ride the economics without footing the R&D bill.
The fine print, minus the snooze
- Ligand gets royalty and milestone rights, not the drug itself.
- Santen’s Ryjunea is already approved in Europe and the UK.
- The treatment is aimed at slowing myopia progression in children, a market with real public-health tailwinds.
Big picture: Ligand is still doing what Ligand does best — buying optionality on other people’s science and hoping the royalty checks age nicely.